We don't build drugs in labs. We engineer the digital information to reprogram biology from the inside out, targeting the unique architecture of every individual tumor.
Generating (Manufacturing-ready) genetic sequences using open-source foundation models.
Cancer is not one disease; it is millions of unique genetic architectures. Traditional "one-size-fits-all" drug development is failing 1 in 6 deaths worldwide.
Generic treatments target broad cohorts, ignoring the extreme genetic heterogeneity of tumors.
Current gene delivery lacks precise targeting, often damaging healthy organs like the liver.
Hundreds of millions wasted in physical wet-lab maintenance and real estate.
Explore how OncoPrint AI reprogram's biology to destroy lung cancer. Unlike toxic chemotherapy, our computational approach uses precision infiltration and targeted destruction.
Our ESM-3 models design molecular "keys" (ligands) that exclusively fit the "locks" (receptors) overexpressed on lung tumor cells. The drug bypasses healthy tissue entirely, traveling as a digital blueprint translated into a physical vehicle.
The transition from raw patient data to manufacturing-ready blueprints in 12 months.
Month 1-3
HIPAA compliant pipelines to ingest NGS genomic files (FASTQ/BAM).
Month 4-6
Isolating driver mutations and optimizing mRNA sequences via Immunostruct.
Month 7-9
Structural ESM-3 models design custom AAV capsids or LNP ligands.
Month 10-12
Launching the compiler for partner labs to synthesize drugs on-site.
By replacing physical labs with computational intelligence, we achieve Enterprise SaaS margins in a historically capital-heavy industry. We don't manufacture drugs; we manufacture the information to build them.
No physical wet-lab footprint or maintenance costs.
Usage-based token model matching software gross margins.
Built on billions in open-source research (ESM-3, OpenFold).
Agnostic architecture adaptable to longevity and rare disease.
Estimated comparison: Traditional Gene Therapy Corp vs. OncoPrint AI Platform Model
OncoPrint AI is currently seeking strategic partnerships and funding to accelerate the deployment of our computational compiler. We are looking for visionary partners who want to transform personalized medicine into an asset-light, highly scalable SaaS ecosystem.
Reach out directly to discuss technical integration, investment opportunities, or to schedule a live demonstration of the pipeline.
Enterprise Architect & Founder
Direct Contact
+91 9958600928